Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 16/20 | 0.73 |
| ▸ | NMUR1 | Q9HB89 | 15/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632647 | 0.89 | NMUR2 (0.84) | NMUR2NMUR1EPHA2 | |
| SCHEMBL2632668 | 0.85 | NMUR2 (0.73) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL10078439 | 0.85 | NMUR2 (0.56) | NMUR2NMUR1NPY1R | |
| SCHEMBL17226114 | 0.84 | NMUR2 (0.68) | NMUR2NMUR1EPHA2NPY1R | |
| SCHEMBL2625064 | 0.81 | NMUR2 (0.64) | NMUR2NMUR1NPY1R | |
| SCHEMBL8808129 | 0.81 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL8808113 | 0.81 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL2632729 | 0.80 | NMUR2 (0.67) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL2628463 | 0.80 | NMUR2 (0.63) | NMUR2NMUR1EPHA2NPY1R | |
| SCHEMBL17226129 | 0.79 | NMUR2 (0.62) | NMUR2NMUR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094898-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094898-A1 | PEPTIDE DERIVATIVE | NPPA, LNPEP, NGLY1 | NMUR2 223/4885NMUR1 200/4885EPHA2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.